The Hospital Burden Of COPD In Canada

Bhutani, Mohit; Bourbeau, Jean; Chan, Charles K.; Field, Stephen K.; FitzGerald, J. Mark; Flood, Diane; Grossman, Ronald F.; Hernández, Paul; Levy, Robert D.; Marciniuk, Darcy; O’Donnell, Denis E.; Stickland, Michael K.; Rea, Renata

doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1500

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Canada, AECOPD account for more hospital days than myocardial infarction, congestive heart failure, or pneumonia 13. In 2008, patients hospitalized with an AECOPD in Canada spent an average of 10 days in hospital at an average cost of approximately $10000 per hospitalization 13. In-hospital mortality rates range from 2.5% to 14% and average 7% in patients with an AECOPD 14.…”

Section: Acute Exacerbations Of Copdmentioning

confidence: 99%

“… 13 In 2008, patients hospitalized with an AECOPD in Canada spent an average of 10 days in hospital at an average cost of approximately $10000 per hospitalization. 13 In-hospital mortality rates range from 2.5% to 14% and average 7% in patients with an AECOPD. 14 The heightened risk of mortality associated with AECOPD extends beyond the period of hospitalization.…”

Section: Acute Exacerbations Of Copdmentioning

confidence: 99%

See 1 more Smart Citation

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations

Field

2011

Clin Med Insights Circ Respir Pulm Med

Self Cite

View full text Add to dashboard Cite

Acute exacerbations of COPD (AECOPD) are major clinical events. They are associated with a more rapid decline in lung function, poorer quality of life scores, and an increased risk of dying. Exacerbations that require hospitalization have particular significance. Approximately 40% of the AECOPD patients who require hospitalization will die in the subsequent year. Since many AECOPD require hospitalization, they account for most of the expense of caring for COPD patients. Treatment with long-acting bronchodilators and combination inhaled corticosteroid/long-acting bronchodilator inhalers reduces but does not eliminate AECOPD. Roflumilast, a selective phosphodiesterase 4 (PDE4) inhibitor, is an anti-inflammatory medication that improves lung function in patients with COPD. In patients with more severe airway obstruction, clinical features of chronic bronchitis, and a history of AECOPD, roflumilast reduces the frequency of AECOPD when given in combination with short-acting bronchodilators, long-acting bronchodilators, or inhaled corticosteroids. It is generally well tolerated but the most common adverse effects include diarrhea, nausea, weight loss, and headaches. In clinical trials, patients treated with roflumilast experienced weight loss that averaged just over 2 kg but was primarily due to the loss of fat tissue. Weight loss was least in underweight patients and obese patients experienced the greatest weight loss. An unexpected benefit of treatment with roflumilast was that fasting blood glucose and hemoglobin A1c levels improved in patients with comorbid type 2 diabetes mellitus. Roflumilast, the first selective PDE4 inhibitor to be marketed, is a promising drug for the management of COPD patients with more severe disease.

show abstract

Section: Acute Exacerbations Of Copdmentioning

confidence: 99%

Section: Acute Exacerbations Of Copdmentioning

confidence: 99%

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations

Field

2011

Clin Med Insights Circ Respir Pulm Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unlike other disease states that similarly have a high mortality, there has been little progress in reducing mortality from COPD and the death rate continues to climb, increasing by as much as 16% in the last 20 years [2]. The morbidity, resource consumption, hospitalizations, and mortality associated with COPD carry a significant social and economic burden [3]. Information about the utility of lung volume reduction in a Canadian setting has been slow to emerge.…”

mentioning

confidence: 99%